SAN DIEGO—Ma Songjiang, President and Director of Gyre Therapeutics, Inc. (NASDAQ:GYRE), reported promoting a complete of $50,553 value of frequent inventory in current transactions. The gross sales occurred on December 26 and 27, 2024, involving 4,000 shares in complete. The transactions come as the corporate’s inventory has declined over 51% year-to-date, in keeping with InvestingPro information.
The shares had been offered at costs starting from $12.58 to $13.05 per share, in keeping with a current submitting. These transactions had been executed below a Rule 10b5-1 buying and selling plan adopted on September 13, 2024. Following these gross sales, Ma Songjiang’s oblique possession, held by a partner, stands at 2,926,467 shares. InvestingPro evaluation signifies the corporate maintains sturdy liquidity with a present ratio of three.72, although it stays unprofitable over the past twelve months.
Gyre Therapeutics, based mostly in San Diego, operates within the pharmaceutical preparations business. The corporate, at present valued at $1.08 billion, maintains a powerful gross margin of 96.23%. Extra insights and monetary metrics can be found via InvestingPro, which options greater than 6 key ideas for traders.
This text was generated with the assist of AI and reviewed by an editor. For extra info see our T&C.
Sir Keir Starmer has instructed Kemi Badenoch to "get on the prepare to Solihull" and…
The east London website which had been earmarked for a Las Vegas-style Sphere leisure venue…
A pub group based by the ex-boss of Greene King is in superior talks to…
The non-public information of M&S prospects has been stolen by hackers throughout an enormous cyber…
The private knowledge of M&S prospects has been stolen by hackers throughout an enormous cyber…
Burberry, the UK's solely international luxurious model, is to chop round 1,700 jobs worldwide over…